Technology.am (June 24, 2009) — Patients with heart disease have a risk of arrhythmias and heart failure. A landmark study has demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization therapy device with defibrillator (CRT-D) versus patients who received only an implanted cardiac defibrillator (ICD-only).
The new CRT-Ds were designed to stop dangerous, life-threatening heart rhythms and improve the heart’s contraction, thereby enabling the device to improve survival and prevent heart failure.
A prior study Multicenter Automatic Defibrillator Implantation Trial (MADIT-II) by Moss and associates in 2002 showed the ICD was effective in reducing mortality.
The current MADIT-CRT study sought to determine if CRT-D could reduce the risk of mortality and heart failure, which affects 5.7 million Americans, and the results are very positive.
MADIT-CRT (Cardiac Resynchronization Therapy) is a clinical trial that enrolled more than 1,800 patients in the United States, Canada and Europe and followed the patients for up to 4½ years.
CRT-D’s are approved for use in patients with severe heart failure (New York Heart Association class III/IV), where they have been shown to reduce heart failure symptoms.